Since the formation of MSI, Dr MacDonald has led MSI’s R&D efforts, focused on pharmaceutical product and clinical development.

Prior to that, Dr MacDonald held leadership positions in a number of small and large pharma biotech companies where he was accountable for a broad range of technical departments and stages of development from discovery through to Phase 2 clinical trials.  Dr MacDonald obtained his Ph.D. in Chemistry from the University of Alberta where his research was focused on enzymology.

Prior to that, she was Vice President Clinical Operations at Cell Therapeutics Inc. (CTI) in Seattle. She oversaw the global clinical project teams for the company’s lead compounds in late stage clinical development, including Pixuvri™ (pixantrone) which led to a marketing approval in Europe, pacritinib (Phase 3), tosedostat (Phase 3) and Opaxio (Phase 3). Before CTI, Dr. Cameron held positions of increasing responsibility at AnorMED (subsequently acquired by Genzyme), including Director of Project Management and Director of Clinical Operations. At AnorMED, she led the clinical team through successful Phase III studies resulting in marketing approval of Mozobil™ in the US and in Europe. Dr. Cameron obtained her Ph.D. in chemistry from the University of Victoria.

He has been a Principal Investigator in over 200 company-sponsored clinical trials and has published over 150 scientific articles in the areas of psychopharmacology, psychobiology, and clinical trials methodology.

Dr Targum received his BA in biology from Colgate University and an MD from Mount Sinai School of Medicine.  He was Professor of Psychiatry and Vice-Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine (Philadelphia) from 1989-1995 and a consultant in psychiatry at the Massachusetts General Hospital in Boston, Massachusetts from 2005-2014.  Dr Targum was also an executive in residence at Oxford BioScience Partners, a venture capital firm from 2005-2011.